Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Month's Exclusive Article 2 Small-Cap Biotechs That Could Reward Patient InvestorsBy Chris Markoch. Originally Published: 12/12/2025. 
At a Glance - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculative investors and patience rarely go together. If you’re considering the small-cap biotech sector, however, patience is a requirement. Most of these companies are still in the clinical stage and do not have commercially available drugs or therapeutics. That means many operate with negative earnings and little to no revenue. Success often hinges on the outcome of a single clinical-stage drug or therapeutic. Amazon's Layoffs Were Just the Beginning
Amazon just slashed 30,000 jobs – the largest layoff in its history – and almost no one's talking about the real reason why. A former hedge fund manager says it's part of a much bigger shift. One that could reshape how we all work, invest, and build wealth in the years ahead. He's spent the last decade preparing for this moment... and just released something that could help everyday Americans get ahead, while there's still time. Full story here Even when a product advances through trials, profitability can be years away. Only after reaching that milestone do companies typically draw the analyst coverage that attracts institutional investment. Still, getting in on one of these medical stocks and having it succeed can produce outsized returns: 3x, 5x or even 10x. Many investors interested in penny stocks respond by spreading a lump sum equally across multiple biotech companies. If it is a numbers game, diversification can be an effective strategy. With that in mind, here are two small-cap biotech stocks that carry significant risks but also the potential for outsized rewards. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular diagnostics company focused on epigenetics-based tests for early cancer detection. Unlike many in this space, Mainz Biomed already has a commercially available product: ColoAlert, the first DNA-based screening tool for colorectal cancer in Europe. On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, a leading digital-health pioneer in Germany. With more than 60,000 new colorectal cancer cases annually in Germany, the market opportunity is meaningful. The company is also developing a non-invasive blood-based screening test for early pancreatic cancer. Mainz Biomed reported positive topline results in October, but commercial approval for that program remains years away. The risks are considerable. ColoAlert is not yet available in the United States, and despite early sales in Europe and plans to expand into South America, revenue is still minimal. That risk is reflected in the company’s Sept. 26 SEC filing, which included “Going Concern” language. Since then, Mainz Biomed filed a $150 million mixed shelf offering. For now, that may be enough to keep MYNZ above $1 and avoid a delisting notice. The company must generate meaningful revenue to change the narrative. If it succeeds, even a small investment today could produce a sizable return. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is another micro-cap biotech pursuing a potentially disruptive antiviral approach, but it also carries the financial risk speculative investors should weigh carefully. The company is developing a novel class of antiviral therapies based on its proprietary “nanoviricide” platform. These drug candidates are designed to mimic human cell surfaces, luring viruses to bind with them and neutralizing the pathogens before they can infect real cells. It’s an innovative concept that, if validated in human trials, could represent a new method for treating infectious disease. NanoViricides’ pipeline includes candidates targeting shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced, with encouraging preclinical data suggesting strong antiviral activity. Like many micro-cap biotechs, NanoViricides remains pre-revenue and dependent on fresh capital to advance its programs. The company has reported limited cash on hand in recent filings, and investors should expect the possibility of future dilution. Still, if even one candidate advances successfully into clinical development, the valuation upside could be substantial. For investors with patience and a high tolerance for risk, NNVC represents a genuine moonshot in the antiviral space.
| 
